September 30, 2014 11:23 AM ET

Pharmaceuticals

Company Overview of Noven Pharmaceuticals, Inc.

Company Overview

Noven Pharmaceuticals, Inc. researches, develops, manufactures, markets, and sells prescription pharmaceutical products. Its products include Vivelle-Dot and Estradot, which are transdermal estrogen patches; CombiPatch and Estalis, which are combination estrogen/progestogen patches; Stavzor, a delayed release valproic acid softgel; Pexeva, a paroxetine mesylate; Lithobid, a lithium carbonate; Brisdelle, a paroxetine capsule for the treatment of vasomotor symptoms associated with menopause; and estradiol transdermal system for the prevention of postmenopausal osteoporosis. It also manufactures Daytrana, a prescription central nervous system stimulant patch system for the treatment of ADHD in ...

11960 SW 144th Street

Miami, FL 33186

United States

Founded in 1987

610 Employees

Phone:

305-253-5099

Fax:

305-251-1887

Key Executives for Noven Pharmaceuticals, Inc.

Chief Executive Officer and President
Age: 48
Chief Financial Officer
Age: 56
Vice President of Operations
Chief Scientific Officer and Vice President
Age: 58
Chief Medical Officer and Executive Vice President of Product Development
Age: 59
Compensation as of Fiscal Year 2014.

Noven Pharmaceuticals, Inc. Key Developments

Noven Receives FDA Approval of New Indication with New Dose for Minivelle(R) (Estradiol Transdermal System)

Noven Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for the prevention of postmenopausal osteoporosis. The FDA initially approved Minivelle in October 2012 to treat moderate to severe vasomotor symptoms (VMS) due to menopause, commonly known as hot flashes. With this new approval, women who are using Minivelle to treat their VMS symptoms have the benefit of also helping to prevent osteoporosis. The new 0.025 mg/day patch is 33% smaller than Minivelle 0.0375 mg/day that is already only about the size of a dime, the planet's smallest estrogen therapy patch ever. Minivelle is now approved with five dosing options -- 0.025 mg/day, 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day, and 0.1 mg/day, with the newly approved, lower dose of 0.025 mg/day indicated for the prevention of postmenopausal osteoporosis only. If a patient uses Minivelle only to prevent osteoporosis from menopause, they should talk with their healthcare provider about whether a different treatment or medicine without estrogens might be better for them. The new lower dose of 0.025 mg/day is expected to be available in pharmacies in January 2015. Noven offers a savings program to help reduce the Minivelle co-pay for eligible patients. Eligible patients pay no more than $15 each month for up to 12 uses on their Minivelle prescriptions.

Noven Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Noven Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Noven Appoints Krista Roberts as Vice President of Operations

Noven Pharmaceuticals, Inc. announced the appointment of Krista Roberts as the company's new Vice President of Operations. In this role, Roberts will be responsible for all Noven manufacturing and related operations, reporting to Jeffrey Eisenberg, Noven's President and Chief Executive Officer. Roberts succeeds Richard Gilbert, who retired in April 2014. Roberts has over 15 years' experience in the pharmaceutical and medical device industries. Prior to joining Noven, she held various positions within Baxter International, serving most recently as Plant Manager of Baxter's 600+ person manufacturing facility in Cleveland, Mississippi. Her prior roles at Baxter included Director of Manufacturing, Manufacturing Manager, Manufacturing Superintendent, Department Engineer, and Manufacturing Supervisor.

Similar Private Companies By Industry

Company Name Region
Novartis Institutes for BioMedical Research, Inc. United States
Mirror Pharmaceuticals LLC United States
Mycosol, Inc. United States
Rapa Holdings Inc. United States
Invivis Pharmaceuticals Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Noven Pharmaceuticals, Inc., please visit www.noven.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.